CXCR4-Mediated Chemokine Signaling Orchestrates the Progression of Conjunctival Melanocytic Lesions
Investigative Ophthalmology & Visual Science · 2025
DOI: 10.1167/iovs.66.11.23 ↗Kurz gefasst
Fachartikel in der Zeitschrift Investigative Ophthalmology & Visual Science, 2025. Verfasst von Ziyue Huang und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Ophthalmology, Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China. Hauptthemen laut MEDLINE: Receptors, CXCR4, Melanoma, Conjunctival Neoplasms, Chemokine CXCL12. Die Arbeit nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Ophthalmology, Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
- State Key Laboratory of Eye Health, Shanghai, China.
- Shanghai Key Laboratory of Orbital Diseases and Ocular Oncology, Shanghai, China.
- Department of Pathology, Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Zitieren
APA
Huang, Z., Zhu, T., Chen, J., Qiu, M., Rao, Y., Jia, R., & Xu, S. (2025). CXCR4-Mediated Chemokine Signaling Orchestrates the Progression of Conjunctival Melanocytic Lesions. Investigative Ophthalmology & Visual Science. https://doi.org/10.1167/iovs.66.11.23
Vancouver
Huang Z, Zhu T, Chen J, Qiu M, Rao Y, Jia R, et al. CXCR4-Mediated Chemokine Signaling Orchestrates the Progression of Conjunctival Melanocytic Lesions. Investigative Ophthalmology & Visual Science. 2025. doi:10.1167/iovs.66.11.23
BibTeX
@article{Huang2025,
author = {Huang, Ziyue and Zhu, Tianyu and Chen, Jie and Qiu, Mingfeng and Rao, Yamin and Jia, Renbing and Xu, Shiqiong},
title = {CXCR4-Mediated Chemokine Signaling Orchestrates the Progression of Conjunctival Melanocytic Lesions},
journal = {Investigative Ophthalmology & Visual Science},
year = {2025},
doi = {10.1167/iovs.66.11.23}
}
EUVIMED